Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

P2400000

Polymyxin B sulfate

European Pharmacopoeia (EP) Reference Standard

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Číslo CAS:
1405-20-5
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

polymyxin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C48H82N16O13.H2O4S/c1-27(2)24-37-47(76)59-32(11-19-52)41(70)56-31(10-18-51)43(72)61-35(14-22-65)39(68)54-21-13-34(45(74)57-33(12-20-53)44(73)64-38(48(77)63-37)25-28-6-4-3-5-7-28)60-42(71)30(9-17-50)58-46(75)36(15-23-66)62-40(69)29(8-16-49)55-26-67;1-5(2,3)4/h3-7,26-27,29-38,65-66H,8-25,49-53H2,1-2H3,(H,54,68)(H,55,67)(H,56,70)(H,57,74)(H,58,75)(H,59,76)(H,60,71)(H,61,72)(H,62,69)(H,63,77)(H,64,73);(H2,1,2,3,4)

InChI key

HNDFYNOVSOOGDU-UHFFFAOYSA-N

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Související kategorie

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Polymyxin B sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Č. produktu
Popis
Stanovení ceny

Pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 5

1 of 5

Polymyxin B-Agarose aqueous glycerol suspension

Sigma-Aldrich

P1411

Polymyxin B-Agarose

Polymyxin B selective supplement for bacteria, sterile, suitable for microbiology

Millipore

P9602

Polymyxin B selective supplement

vibrant-m

C2700000

Colistin sulfate

vibrant-m

N0400000

Neomycin sulphate

Fosfomycin calcium European Pharmacopoeia (EP) Reference Standard

Y0000782

Fosfomycin calcium

H Deborah Chen et al.
PLoS genetics, 8(12), e1003060-e1003060 (2013-01-10)
Changes in gene regulatory circuits often give rise to phenotypic differences among closely related organisms. In bacteria, these changes can result from alterations in the ancestral genome and/or be brought about by genes acquired by horizontal transfer. Here, we identify
Hiroyuki Hirasawa et al.
Blood purification, 34(2), 164-170 (2012-10-26)
Since the introduction of the new pathophysiological concept of pathogen-associated molecular patterns (PAMPS) and alarmins, endotoxin has been recognized as only one of the PAMPS. It is widely accepted that hypercytokinemia plays a pivotal role in the pathophysiology of sepsis.
Marco M Domingues et al.
Biopolymers, 98(4), 338-344 (2012-11-30)
Antibiotic resistance is an increasingly severe health problem. Antimicrobial peptides (AMPs) are being developed in order to overcome this problem, due lower bacterial resistance. Polymyxin B is an AMP with bactericidal effect on Gram-negative bacteria due to its high affinity
Ana M Sandri et al.
The Journal of antimicrobial chemotherapy, 68(3), 674-677 (2012-11-28)
To evaluate the pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis (CVVHD) after intravenous administration of unadjusted dosage regimens. Two critically ill patients had eight blood samples collected during a 12 h interval on days 8 and 10
Saurabh Piparsania et al.
The Turkish journal of pediatrics, 54(5), 548-554 (2013-02-23)
Central nervous system infections due to multi- and pan-drug resistant Acinetobacter baumannii are an emerging problem in intensive care patients. A high mortality rate is seen in neonatal and central nervous system infections. Treatment can be prolonged and challenging. Polypeptide
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.